| Literature DB >> 28768983 |
Rie Tohge1, Yuya Shinoto1, Makio Takahashi1.
Abstract
The incidence of co-infection with Treponema pallidum and human immunodeficiency virus (HIV) is increasing in developing and developed countries. The neurological complications of both infections occasionally occur simultaneously during a clinical course. We herein report the case of an HIV carrier with syphilitic meningomyelitis and subclinical optic neuropathy. The patient presumably had latent syphilis and slowly developed longitudinally extensive transverse myelitis (LETM). A cerebrospinal fluid examination confirmed the diagnosis of active neurosyphilis based on an elevated T. pallidum hemagglutination assay index. A change in the patient's immune status, possibly due to HIV, might have converted the syphilis from latent to active, leading to LETM of the spinal cord.Entities:
Keywords: TPHA index; human immunodeficiency virus; longitudinally extensive transverse myelitis; optic neuropathy; syphilitic meningomyelitis
Mesh:
Year: 2017 PMID: 28768983 PMCID: PMC5577089 DOI: 10.2169/internalmedicine.56.8236
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271
Figure 1.On contrast abdominal computed tomography, the liver and spleen were normal in size and shape.
Figure 2.The patient’s clinical course. Serum HBsAg was negative, and HBV-DNA was present at 2.6 log copies/mL before chemotherapy. Entecavir (ETV) was used during R-THP-COP chemotherapy and the subsequent 14 months. Serum HBV-DNA levels remained undetectable, and serum gammaglobulin levels were within the normal range. ETV was discontinued at 14 months after the end of chemotherapy. However, serum HBV-DNA became positive at 24 months and increased to 3.3 log copies/mL at 27 months. In addition, serum HBsAg also reverted. After restarting ETV at 28 months, serum HBV-DNA and HBsAg immediately turned negative. Anti-HBs became positive for the first time at 31 months and remained positive at 46 months, whereas ETV was re-discontinued at 36 months.
Figure 3.Details of the clinical course from 24 to 29 months after the end of chemotherapy. Serum HBV-DNA became positive at 24 months and increased to 3.3 log copies/mL at 27 months. HBsAg, HBeAg and HBcrAg reverted at the same time. Two weeks later, laboratory data showed a further increase in the serum HBV-DNA levels and reconversion of HBeAg without elevation of serum ALT levels. The patient started taking entecavir (ETV) again at 28 months. After restarting ETV, serum HBV-DNA, HBsAg, HBeAg and HBcrAg immediately turned negative.
Clinical Characteristics in Syphilitic Meningomyelitis and Comparison with HIV Myelitis.
| Case 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | This | Syphilitic meningomyelitis | HIV myelitis | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ref 3 | 4 | 5 | 6 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | case | n=13 | n=4 | |
| Age | 46 | 63 | 63 | 35 | 30 | 36 | 38 | 46 | 32 | 28 | 31 | 57 | 49 | 42.6±6.7 (28-63) | 33.5±5.0 (29-40) |
| Sex | M | M | M | M | F | M | M | M | M | M | M | F | M | M: 11, F: 2 | M: 4, F: 0 |
| Symptoms duration (d) | 7 | 12 | 60 | 14 | 30 | 120 | 120 | 14 | 120 | 180 | 10 | 3 | 150 | 64.6±34.7 (3-180) | 23.6±13.5 (7-35) |
| Serum HIV antibody (+) | - | - | - | - | - | - | - | NA | - | - | NA | - | + | 1 | 4 |
| MSM | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | + | 1 | 4 |
| Frequent period | <6 years after syphilitic infection | Early phase of HIV infection | |||||||||||||
| Neurological symptoms | |||||||||||||||
| Superficial sensory deficit | + | - | + | NA | NA | + | + | + | + | + | + | + | + | 10/11, 91% | 3/4 |
| Hyperreflexia | + | - | - | NA | NA | + | + | + | + | + | + | + | + | 9/11, 82% | 2/4 |
| Weakness in extremities | - | + | + | NA | NA | + | + | - | + | + | + | + | - | 8/11, 73% | 3/4 |
| Impaired deep sense | - | - | - | NA | NA | + | + | + | - | + | - | + | + | 6/11, 55% | 0/4 |
| Urinary disturbance | - | - | + | NA | NA | - | + | + | + | - | + | - | + | 6/11, 55% | 3/4 |
| Pain | + | + | - | NA | NA | + | + | - | - | - | - | - | - | 4/11, 36% | 3/4 |
| Areflexia | - | - | - | NA | NA | - | - | - | - | - | - | - | - | 0/11 | 1/4 |
| Physical symptoms | |||||||||||||||
| Rash | - | - | + | NA | NA | - | - | - | - | + | - | - | - | 2/11, 18% | 2/4 |
| Fever | - | - | + | NA | NA | - | - | - | - | - | - | - | - | 1/11, 9% | 3/4 |
| Fatigue | - | - | - | NA | NA | - | - | - | - | - | - | - | - | 0/11 | 2/4 |
| Dry cough | - | - | - | NA | NA | - | - | - | - | - | - | - | - | 0/11 | 2/4 |
| Sore throat | - | - | - | NA | NA | - | - | - | - | - | - | - | - | 0/11 | 2/4 |
| Pharyngeal candidiasis | - | - | - | NA | NA | - | - | - | - | - | - | - | - | 0/11 | 2/4 |
| CSF analysis | |||||||||||||||
| Cell count (/μL) | 113 | 303 | 498 | 115 | 170 | 346 | 18 | ↑ | 40 | 196 | 120 | ↑ | 202 | 192.8±83.8 (18-498) | 108.8±114.6 (8-302) |
| % lymphocytes (%) | 100 | 84 | 63 | 85 | 90 | 99 | 72 | NA | 100 | 97 | 100 | NA | 95 | ||
| Protein (mg/dL) | 72 | 92 | 200 | 123 | 57 | 243 | 88 | ↑ | 40 | 109 | 94 | Normal | 79 | 108.8±36.0 (40-243) | 128.5±141.5 (29-343) |
| Immunological reaction for syphilis | iTPA index↑ | RPR+ | VDRL+ | VDRL+ | VDRL+ | FTA+ TPHA+ | VDRL+ | + | VDRL+ | VDRL+ FTA+ | TPHA+ VDRL+ | VDRL+ | TPHA index↑ | iTPA or TPHA index↑ RPR+, VDRL+, FTA+ | NA |
| Laboratory test | Blood HIV-RNA copy↑(12,900-2,400,000 cp/mL) | ||||||||||||||
| MRI findings (locations) | T6-Con | T6-T11 | WS | T4-Con | WS | C-T | T6-T7 | T | T5-T12 | T6-T8 | NA | WS | C4-T6 | ||
| LETM | + | + | + | + | + | + | - | + | + | + | - | + | + | 11/13, 85% | 1/4 |
| Gadolinium-enhancement | + | + | + | NA | NA | + | + | + | NA | NA | + | + | + | 9/13, 69% | 1/4 |
| No abnormal lesion | - | - | - | - | - | - | - | - | - | - | - | - | - | 0/13 | 1/4 |
| Treatment | |||||||||||||||
| Antiluetic therapy | PCG | CTRX | PCG | PCG | PCG | PCG | PCG | AB | PCG | PCG | PCG | PCG | PCG | 13/13, 100% | NA |
| Steroids | mPSL | mPSL | DEX | mPSL | - | - | PSL | - | - | DEX | PSL | DEX | mPSL | 9/13, 69% | 2/4 |
| HAART | - | - | - | - | - | - | - | - | - | - | - | - | - | 0/13 | 2/4 |
| Human immunoglobulin | - | - | - | - | - | - | - | - | - | - | - | - | - | 0/13 | 1/4 |
| Observation | - | - | - | - | - | - | - | - | - | - | - | - | - | 0/13 | 1/4 |
Ref: reference, M: male, F: female, NA: not applicable, MSM: men who have sex with men, iTPA: intrathecal Treponemapallidum antibody, VDRL: venereal disease research laboratory, FTA: fluorescent treponemal antibody, TPHA: treponema pallidum hemagglutination assay, T: thoracic, WS: whole spinal cord, Con: conus, C: cervical, LETM: longitudinally extensive transverse myelitis, PCG: penicillin G, AB: antibiotics, CTRX: ceftriaxone, mPSL: methyl-prednisolone, DEX: dexamethasone, PSL: prednisolone, HAART: highly activated anti-retroviral therapy